rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    KTTAW
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
      Oct 28Yahoo FinanceKTTAKTTAW
      Pasithea reports prolonged stable disease in PAS-004 cancer trial
      Oct 23Investing.comKTTAKTTAW
      Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
      Oct 23Yahoo FinanceKTTAKTTAW
      Pasithea at Chardan conference: early nf1 data, safety focus
      Oct 20Investing.comKTTAKTTAW
      Pasithea Therapeutics Announces Nasdaq Warrant Expiration

      Detailed price information for Pasithea Therapeutics Corp (KTTA-Q) from The Globe and Mail including charting and trades.

      Sep 17The Globe and MailKTTAKTTAW
      Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference

      - Pasithea has been selected to present cutaneous neurofibromas (CN) clinical data in an oral presentation - Pasithea has been selected to present plexiform neurofibromas (PN) clinical data in a poster presentation - The European Neurofibromatosis Conference 2026 will take place in Vienna, Austria, from November 12–14, 2026 MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004,

      Sep 14Yahoo FinanceKTTAKTTAW
      Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

      -- Company will hold one-on-one investor meetings at the 12th Annual Cantor Global Healthcare Conference (September 9-11) and will present at the H.C. Wainwright 28th Annual Global Investment Conference (September 14-16) -- MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases inc

      Sep 3Yahoo FinanceKTTAKTTAW
      Pasithea Therapeutics Receives Nasdaq Extension on Listing Compliance

      Detailed price information for Pasithea Therapeutics Corp (KTTA-Q) from The Globe and Mail including charting and trades.

      Aug 22The Globe and MailKTTAKTTAW

      This is the newest page. Registered accounts read further back.